Theo Lorenzini

Ismaninger Str. 22
Munich, BY 81675, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 16 publications

Impact of different PSMA PET-based eligibility criteria on outcome of [177Lu]Lu-PSMA radioligand therapy using [18F]rhPSMA-7/[18F]rhPSMA-7.3 (Flotufolastat).

Impact of different PSMA PET-based eligibility criteria on outcome of [177Lu]Lu-PSMA radioligand therapy using [18F]rhPSMA-7/[18F]rhPSMA-7.3 (Flotufolastat).

Journal: EJNMMI research

Published: January 12, 2026

RIG-I agonists promote antigen-spreading and facilitate durable CAR-T responses in pancreatic ductal adenocarcinoma.

RIG-I agonists promote antigen-spreading and facilitate durable CAR-T responses in pancreatic ductal adenocarcinoma.

Journal: Journal for immunotherapy of cancer

Published: December 29, 2025

Prognostic Value of [18F]Flotufolastat PET Using Visual RECIP in Docetaxel-Treated Metastatic Prostate Cancer.

Prognostic Value of [18F]Flotufolastat PET Using Visual RECIP in Docetaxel-Treated Metastatic Prostate Cancer.

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine

Published: November 06, 2025

Liquid Biopsy Biomarkers in Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Prostate-Specific Membrane Antigen Radioligand Therapy: Protocol for a Prospective, Longitudinal Multicenter Observational Study.

Liquid Biopsy Biomarkers in Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Prostate-Specific Membrane Antigen Radioligand Therapy: Protocol for a Prospective, Longitudinal Multicenter Observational Study.

Journal: JMIR research protocols

Published: October 29, 2025

Value of a repeat 18F-flotufolastat PET scan following a negative scan in patients with suspected biochemical recurrence of prostate cancer after radical prostatectomy.

Value of a repeat 18F-flotufolastat PET scan following a negative scan in patients with suspected biochemical recurrence of prostate cancer after radical prostatectomy.

Journal: European journal of nuclear medicine and molecular imaging

Published: September 11, 2025

The German Cancer Consortium (DKTK) multi-center prospective phase 1/2 68Ga-PSMA-11 PET-imaging trial in newly-diagnosed high-risk prostate cancer: Safety and diagnostic accuracy compared to histopathology and their impact on patient management.

The German Cancer Consortium (DKTK) multi-center prospective phase 1/2 68Ga-PSMA-11 PET-imaging trial in newly-diagnosed high-risk prostate cancer: Safety and diagnostic accuracy compared to histopathology and their impact on patient management.

Journal: European journal of nuclear medicine and molecular imaging

Published: June 30, 2025

[18F]Flotufolastat PET/MRI in Patients with Suspected Prostate Cancer: Correlation with Histopathologic Biopsy Results.

[18F]Flotufolastat PET/MRI in Patients with Suspected Prostate Cancer: Correlation with Histopathologic Biopsy Results.

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine

Published: May 16, 2025

[68Ga]Ga-PSMA-11 PET Tumor Volume Predicts Overall Survival of Patients with Metastatic Prostate Cancer Undergoing Taxane-Based Chemotherapy.

[68Ga]Ga-PSMA-11 PET Tumor Volume Predicts Overall Survival of Patients with Metastatic Prostate Cancer Undergoing Taxane-Based Chemotherapy.

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine

Published: April 22, 2025

CXCR4-directed endoradiotherapy with [177Lu]Pentixather added to total body irradiation for myeloablative conditioning in patients with relapsed/refractory acute myeloid leukemia.

CXCR4-directed endoradiotherapy with [177Lu]Pentixather added to total body irradiation for myeloablative conditioning in patients with relapsed/refractory acute myeloid leukemia.

Journal: Theranostics

Published: July 20, 2024

Dissection of single-cell landscapes for the development of chimeric antigen receptor T cells in Hodgkin lymphoma.

Dissection of single-cell landscapes for the development of chimeric antigen receptor T cells in Hodgkin lymphoma.

Journal: Blood

Published: August 16, 2023

Bispecific antibodies redirect synthetic agonistic receptor modified T cells against melanoma.

Bispecific antibodies redirect synthetic agonistic receptor modified T cells against melanoma.

Journal: Journal for immunotherapy of cancer

Published: April 16, 2023

In vivo dynamics and anti-tumor effects of EpCAM-directed CAR T-cells against brain metastases from lung cancer.

In vivo dynamics and anti-tumor effects of EpCAM-directed CAR T-cells against brain metastases from lung cancer.

Journal: Oncoimmunology

Published: January 23, 2023

Showing 1-12 of 16

Last Updated: 09/26/2026